CASDIN CAPITAL, LLC

{{ Info.Overview }}
Revenue: {{ Info.Revenue | formatUSD }} Headquarters: {{ Info.Headquarters }}
{{ Info.Homepage }}

Adviser Profile

As of Date:

03/30/2024

Adviser Type:

- Large advisory firm

Number of Employees:

33 -13.16%

of those in investment advisory functions:

12 -7.69%

Registration:

SEC, Approved, 7/31/2017

Other registrations (1)
AUM:

2,643,698,992 -2.29%

of that, discretionary:

2,643,698,992 -2.29%

GAV:

2,643,698,992 -2.29%

Avg Account Size:

330,462,374 -2.29%

SMA’s:

NO

Private Funds:

6

Contact Info

212 xxxxxxx

Websites :
Client Types:

+

Advisory Activities:

+

Compensation Arrangments:

+

Reported AUM

Discretionary
Non-discretionary
5B 4B 4B 3B 2B 1B 743M
2017 2018 2019 2020 2021 2022 2023

Recent News

Hedge Fund and Insider Trading News: Bodenholm Capital, Elliott Investment Management, Brigade Capital Management, AQR Capital Management, Casdin Capital, Kirby Corporation (KEX), Arista Networks Inc (ANET), and More
11/02/2021

feedproxy.google.com

Casdin Capital, LLC Buys Verve Therapeutics Inc, Century Therapeutics Inc, Singular Genomics ...
08/24/2021

Related Stocks: SRPT, RVMD, GBT, ADPT, VERV, IPSC, OMIC, AMRS, GBIO, ME, BNR, ADVM, TSHA, DYN, CDAK,

gurufocus.com

YouTube says it's doing better at removing videos that go against its policies
04/06/2021

As part of its quarterly Community Guidelines Enforcement Report, YouTube plans to share a new statistic called VVR. Short for Violative View Rate, the stat details the percentage of views on ...

yahoo.com

Biden's electric vehicle ambitions may send Tesla stock skyrocketing to $1,300: analyst
04/06/2021

Tesla shares (TSLA) are getting a nice pop on Monday following much better than expected first quarter delivery numbers, but the real upside to shares in the medium-term will be in part due to efforts out of the Biden administration to get people into ...

Yahoo Finance

CareDx Inc.
04/05/2021

Stocks: Real-time U.S. stock quotes reflect trades reported through Nasdaq only; comprehensive quotes and volume reflect trading in all markets and are delayed at least 15 minutes. International ...

Barrons

Health/Life Sciences
04/03/2021

Consider the difficulties many of us face when we need medical procedures, tests or referrals. Now imagine you lived in a developing country where these challenges can be significantly greater ...

geekwire.com


Private Funds Structure

Fund Type Count GAV
Hedge Fund 3 $1,969,636,424
Private Equity Fund 2 $645,517,881
Venture Capital Fund 1 $28,544,687

Similar advisers

Adviser Hedge Fund Liquidity Fund Private Equity Fund Real Estate Fund Securitized Asset Fund Venture Capital Fund Other Fund Total Private Fund GAV AUM # funds
AVEGO MANAGEMENT, LLC 195.6m - 573.8m - - 91.7m - 952.8m 861.1m 6
BLOCKTOWER CAPITAL ADVISORS LP 452.7m - 8.1m - - 157.4m - 775.7m 1.7b 6
SALUDA GRADE ASSET MANAGEMENT LLC 2.5b - 45.0m - - 58.6m - 2.7b 2.6b 5
CRAIG DRILL CAPITAL CORPORATION 46.5m - 17.3m - - 5.1m - 73.9m - 4
BLUE WATER LIFE SCIENCE ADVISORS, LP 280.0m - 17.7m - - - - 297.7m 160.2m 5
BRIGHTWOOD CAPITAL ADVISORS, LLC 3.6b - 339.0m - 1.5b 241.7m - 5.9b 6.0b 30
TIMUCUAN ASSET MANAGEMENT INC 741.3m - 440.1k - - - - 741.7m 3.3b 2
STEADVIEW CAPITAL MANAGEMENT LLC 2.7b - 162.1m - - - - 2.9b 2.9b 7
HINES CAPITAL ADVISORS LLC 1.4b - 509.0m - - - - 1.9b 2.9b 5
KEEL POINT, LLC 32.1m - 1.7m - - - - 33.8m 2.9b 2

Private Funds



Employees




Top Holdings

Stock Ticker Stock Name $ Position % Position $ Change # Change
76155X100 REVOLUTION MEDICINES INC $163,899,747 16.00% 227.00% 216.00%
09062W204 BIOLIFE SOLUTIONS INC $141,491,431 14.00% 32.00% 12.00%
803607100 SAREPTA THERAPEUTICS INC $97,056,795 10.00% -21.00% 0.00%
75943R102 RELAY THERAPEUTICS INC $81,341,252 8.00% 40.00% 7.00%
86366E106 STRUCTURE THERAPEUTICS INC $44,504,499 4.00% -28.00% -13.00%
92539P101 VERVE THERAPEUTICS INC $41,946,770 4.00% 7.00% 2.00%
02043Q107 ALNYLAM PHARMACEUTICALS INC $37,324,950 4.00% 5.00% -3.00%
452327109 ILLUMINA INC $43,582,120 4.00% 1170.00% 1152.00%
45826J105 INTELLIA THERAPEUTICS INC $44,210,500 4.00% 19.00% 23.00%
24823R105 DENALI THERAPEUTICS INC $27,898,000 3.00% 4.00% 0.00%

Brochure Summary

Overview

Casdin Capital, LLC (hereinafter, the “Firm,” “we,” “us” or “our”), founded in 2012, is an investment advisory services firm that currently provides investment management services to its client funds. Eli Casdin is the manager and owner of the Firm and, in such capacity, has sole discretion on all investment and trading decisions. Mr. Casdin is likewise the manager of our affiliates, Casdin Partners GP, LLC, Casdin Venture Opportunities Fund GP, LLC, Casdin Private Growth Equity Fund GP, LLC, and Casdin Private Growth Equity Fund II GP, LLC, which act as general partners to certain of our current client funds (the “General Partners”) The Firm currently provides its services to eight client funds, each of which is a pooled investment vehicle, or more specifically, a private investment fund, the securities of which are offered to certain qualified investors on a private placement basis: Casdin Partners, L.P., a Delaware limited partnership (“Casdin Partners”), Casdin Partners Offshore, Ltd. (“Casdin Offshore”), a Cayman Islands exempted company, Casdin Partners Master Fund, L.P., a Cayman Islands exempted limited partnership, which is a private pooled investment “master fund” in a master-feeder structure with Casdin Partners and Casdin Offshore (the “Master Fund”), Casdin Partners FO1-MSV, L.P., a Delaware limited partnership (“FO1”); Casdin Amplify Fund, L.P., a Delaware limited partnership (“Amplify”) (together the “ Hedge Funds”); Casdin Venture Opportunities Fund, L.P., a Delaware limited partnership (“Casdin Venture”), Casdin Private Growth Equity Fund, L.P., a Delaware limited partnership (“Casdin Private Growth”), and Casdin Private Equity Growth Fund II, L.P., a Delaware limited partnership (“Casdin Private Growth II”) (together the “PE Funds"). While we consider both Casdin Partners and Casdin Offshore as client funds, each invests substantially
all of its investable assets in the Master Fund through which we conduct these fund’s investment activities. In providing our advisory services to our client funds, we seek to realize superior long-term adjusted total returns by primarily investing in underappreciated companies with innovative business models in the life sciences and healthcare industry. Our portfolio is generally comprised of small to mid-sized issuers in the following life sciences and healthcare sub-sectors: life sciences instrumentation and information technology, medical testing, drug development and distribution, synthetic biology and agriculture, livestock management and energy production. In addition, we also have discretion to invest in certain foreign equity securities if we determine that investments in such securities could generate risk-adjusted returns for our client funds. We tailor our advisory services to the individual needs and specified investment mandates of our client funds. We adhere to the investment strategy set forth in the private placement memorandum of each client fund. We do not, however, tailor our advisory services to the individual needs or any specified investment mandates of the investors of our client funds and those investors may not impose restrictions on investing in certain securities or types of securities. We have full investment discretion in investing on behalf of our client funds and will not be required to seek approval from a client fund or such client fund’s investors with respect to a client fund’s investments. We do not participate in any wrap-fee programs. As of December 31, 2022, we have regulatory assets under management of $2,705,553,673. We manage 100% of our regulatory assets under management on a discretionary basis and none of our regulatory assets under management on a non-discretionary basis.